Trials / Completed
CompletedNCT02709187
DP-R208 Pharmacokinetic Study
DP-R208 Pharmacokinetic Study Phase I
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Alvogen Korea · Industry
- Sex
- Male
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R208 (Candesartan cilexetil 8mg/Rosuvastatin 10mg), a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DP-R208 | Investigational product is prescribed to all of randomized subjects |
| DRUG | Candesartan cilexetil | Investigational product is prescribed to all of randomized subjects |
| DRUG | Rosuvastatin | Investigational product is prescribed to all of randomized subjects |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2016-03-15
- Last updated
- 2016-06-08
Source: ClinicalTrials.gov record NCT02709187. Inclusion in this directory is not an endorsement.